NextCell Pharma (Q1 review): Gearing up ahead of readout(s) after summer - Redeye

Q1 2026 was operationally a step forward on multiple fronts: new long-term data from NXTCL-T1D reinforced the durability of the treatment effect, FUJIFILM Biosciences commercially launched NextCell-Cord RUO after the period, and the company closed a SEK15m directed issue to prolong cash runway. The phase ll-readout after the summer remains the most critical event in the near-term.

Länk till analysen i sin helhet: https://www.redeye.se/research/1166465/nextcell-pharma-q1-review-gearing-up-ahead-of-readouts-after-summer?utm_source=finwire&utm_medium=RSS